Inovio Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Inovio Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Inovio Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Inovio Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Inovio Pharmaceuticals Inc (Inovio) is a clinical-stage biotechnology company focused on developing DNA medicines to combat HPV-related diseases, cancer, and infectious diseases. The company utilizes proprietary technology to design DNA plasmids and investigational Cellectra devices for optimal delivery into the body’s cells. Inovio's major products include DNA medicine candidates like INO-3112 and INO-3107, targeting specific diseases such as recurrent respiratory papillomatosis and HPV-related cancers. The company's products are designed for patients with HPV-associated diseases and various cancers, with applications in the healthcare and pharmaceutical industries. It collaborates with other pharmaceutical companies for clinical trials and product development. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
Headquarters
United States of America
Address
Suite 110, 660 W. Germantown Pike, Plymouth Meeting, Pennsylvania, 19462
Website
www.inovio.com
Telephone
1 267 4404200
No of Employees
112
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INO (NASD)
Revenue (2024)
$65,300
-70%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
20.8%
(2024 vs 2023)
Market Cap*
$66.9M
Net Profit Margin (2024)
XYZ
-164.0%
(2024 vs 2023)
* As of and is in US$
Inovio Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| INO-5401: BRCA 1/2 Mutation |
| INO-4201: Ebola Booster |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In July, the company received an advanced therapy medicinal product certificate for quality and non-clinical data for lead candidate INO-3107 from the European Medicines Agency. |
| 2024 | Regulatory Approval | In July, the company received an innovation passport designation from the UK government's innovative licensing and access pathway for its INO-3107. |
| 2024 | Contracts/Agreements | In January, the company and Coherus BioSciences entered into a clinical collaboration and supply agreement to assess the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential to treat patients with locoregionally advanced, high-risk, HPV16/18. |
Competitor Comparison
| Key Parameters | Inovio Pharmaceuticals Inc | Roche Holding AG | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Plymouth Meeting | Basel | Rahway | New York City | North Chicago |
| State/Province | Pennsylvania | Basel-Stadt | New Jersey | New York | Illinois |
| No. of Employees | 112 | 112,774 | 75,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simon X. Benito | Chairman | Executive Board | 2019 | 81 |
| Jacqueline E. Shea, PhD | Chief Executive Officer; President; Director | Executive Board | 2022 | 60 |
| Peter D. Kies | Chief Financial Officer | Senior Management | 2002 | 62 |
| Rob Crotty | Secretary; General Counsel; Chief Compliance Officer | Senior Management | 2021 | - |
| Michael Sumner, MD | Head - Development; Chief Medical Officer | Senior Management | 2022 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer